Crescent Biopharma Advances CR-001 Clinical Trial for Solid Tumors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2026
0mins
Source: Newsfilter
- Trial Launch: Crescent Biopharma is conducting the ASCEND global clinical trial to evaluate CR-001's safety and efficacy in non-small cell lung cancer and other solid tumors, aiming to enroll 290 patients, demonstrating the company's proactive approach in cancer treatment.
- Data Release Expectations: Initial clinical data from the ASCEND trial, including safety, pharmacokinetics, and antitumor activity metrics, are anticipated in Q1 2027, potentially providing critical insights into CR-001's market viability.
- Collaborative Development Plans: The strategic partnership with Sichuan Kelun-Biotech will facilitate CR-001's clinical trials in China, set to commence in H1 2026, indicating the company's intent to expand its global footprint.
- Innovative Drug Design: CR-001, a PD-1 x VEGF bispecific antibody, aims to restore T cells' ability to recognize tumor cells while inhibiting blood supply to tumors, offering new therapeutic options that could transform the treatment landscape for solid tumors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBIO
Wall Street analysts forecast CBIO stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.720
Low
22.00
Averages
28.20
High
35.00
Current: 19.720
Low
22.00
Averages
28.20
High
35.00
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crescent Biopharma to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 p.m. ET in New York, showcasing its latest advancements in cancer treatment.
- Key Conference Dates: Additionally, the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 8:40 a.m. ET in Miami, further enhancing its market visibility.
- Webcast Availability: Each presentation will be available via live webcast in the Investors section of Crescent Biopharma's website, with replays accessible for 90 days, ensuring investors can stay informed on critical updates.
- Company Vision and Pipeline: Crescent Biopharma aims to become a world-leading oncology company, with a clinical-stage pipeline that includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, designed to rapidly advance potentially transformative therapies for various solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 16,950 stock options to two non-executive employees on May 28, 2026, as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent.
- Option Terms: The options have an exercise price of $21.47 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and the remainder vesting monthly, ensuring continuous service.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in attracting key talent.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing multiple potentially transformative therapies in clinical development to provide more effective treatment options for cancer patients.
See More
Crescent Biopharma Advances CR-001 Clinical Trial for Solid Tumors
- Trial Launch: Crescent Biopharma is conducting the ASCEND global clinical trial to evaluate CR-001's safety and efficacy in non-small cell lung cancer and other solid tumors, aiming to enroll 290 patients, demonstrating the company's proactive approach in cancer treatment.
- Data Release Expectations: Initial clinical data from the ASCEND trial, including safety, pharmacokinetics, and antitumor activity metrics, are anticipated in Q1 2027, potentially providing critical insights into CR-001's market viability.
- Collaborative Development Plans: The strategic partnership with Sichuan Kelun-Biotech will facilitate CR-001's clinical trials in China, set to commence in H1 2026, indicating the company's intent to expand its global footprint.
- Innovative Drug Design: CR-001, a PD-1 x VEGF bispecific antibody, aims to restore T cells' ability to recognize tumor cells while inhibiting blood supply to tumors, offering new therapeutic options that could transform the treatment landscape for solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On May 11, 2026, Crescent Biopharma approved the grant of 129,075 stock options to five non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Option Terms: The options have an exercise price of $18.52 per share and a 10-year term, with one-fourth of the options vesting on the first anniversary of employment and the remainder vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to attracting high-quality talent while enhancing transparency and investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company by advancing its clinical pipeline, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, to provide innovative treatment options for cancer patients.
See More
Crescent Biopharma Announces Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to participate in several investor conferences in May 2026, including the BofA Securities Healthcare Conference on May 13, the Stifel Virtual Targeted Oncology Forum on May 20, and the TD Cowen 7th Annual Oncology Innovation Summit on May 26, showcasing its advancements in cancer treatment.
- Live Webcast Availability: Each presentation will be available via live webcast on Crescent's investor website, with replays accessible for 90 days post-event, ensuring investors can stay updated on the company's latest developments and strategic direction.
- Clinical Pipeline Overview: Crescent's clinical pipeline features its lead program, a PD-1 x VEGF bispecific antibody, along with novel antibody-drug conjugates (ADCs), aiming to rapidly advance potentially transformative therapies for various solid tumors through multiple treatment modalities.
- Company Vision: Crescent Biopharma envisions becoming a world-leading oncology company focused on delivering the next wave of therapies for cancer patients, reflecting its innovation and market potential in the biopharmaceutical sector.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma's Board approved the grant of 12,525 stock options to two non-executive employees on April 23, 2026, as equity inducement awards under the 2025 Employment Inducement Incentive Award Plan, highlighting the company's commitment to attracting talent.
- Option Terms: The options have an exercise price of $25.70 per share and a 10-year term, designed to incentivize employees for long-term service and foster innovation in cancer treatment.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service and enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, to rapidly develop potentially transformative treatments for various solid tumors.
See More
Crescent Biopharma to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 p.m. ET in New York, showcasing its latest advancements in cancer treatment.
- Key Conference Dates: Additionally, the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 8:40 a.m. ET in Miami, further enhancing its market visibility.
- Webcast Availability: Each presentation will be available via live webcast in the Investors section of Crescent Biopharma's website, with replays accessible for 90 days, ensuring investors can stay informed on critical updates.
- Company Vision and Pipeline: Crescent Biopharma aims to become a world-leading oncology company, with a clinical-stage pipeline that includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, designed to rapidly advance potentially transformative therapies for various solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 16,950 stock options to two non-executive employees on May 28, 2026, as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent.
- Option Terms: The options have an exercise price of $21.47 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and the remainder vesting monthly, ensuring continuous service.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in attracting key talent.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing multiple potentially transformative therapies in clinical development to provide more effective treatment options for cancer patients.
See More
Crescent Biopharma Advances CR-001 Clinical Trial for Solid Tumors
- Trial Launch: Crescent Biopharma is conducting the ASCEND global clinical trial to evaluate CR-001's safety and efficacy in non-small cell lung cancer and other solid tumors, aiming to enroll 290 patients, demonstrating the company's proactive approach in cancer treatment.
- Data Release Expectations: Initial clinical data from the ASCEND trial, including safety, pharmacokinetics, and antitumor activity metrics, are anticipated in Q1 2027, potentially providing critical insights into CR-001's market viability.
- Collaborative Development Plans: The strategic partnership with Sichuan Kelun-Biotech will facilitate CR-001's clinical trials in China, set to commence in H1 2026, indicating the company's intent to expand its global footprint.
- Innovative Drug Design: CR-001, a PD-1 x VEGF bispecific antibody, aims to restore T cells' ability to recognize tumor cells while inhibiting blood supply to tumors, offering new therapeutic options that could transform the treatment landscape for solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On May 11, 2026, Crescent Biopharma approved the grant of 129,075 stock options to five non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness.
- Option Terms: The options have an exercise price of $18.52 per share and a 10-year term, with one-fourth of the options vesting on the first anniversary of employment and the remainder vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to attracting high-quality talent while enhancing transparency and investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company by advancing its clinical pipeline, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates, to provide innovative treatment options for cancer patients.
See More
Crescent Biopharma Announces Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to participate in several investor conferences in May 2026, including the BofA Securities Healthcare Conference on May 13, the Stifel Virtual Targeted Oncology Forum on May 20, and the TD Cowen 7th Annual Oncology Innovation Summit on May 26, showcasing its advancements in cancer treatment.
- Live Webcast Availability: Each presentation will be available via live webcast on Crescent's investor website, with replays accessible for 90 days post-event, ensuring investors can stay updated on the company's latest developments and strategic direction.
- Clinical Pipeline Overview: Crescent's clinical pipeline features its lead program, a PD-1 x VEGF bispecific antibody, along with novel antibody-drug conjugates (ADCs), aiming to rapidly advance potentially transformative therapies for various solid tumors through multiple treatment modalities.
- Company Vision: Crescent Biopharma envisions becoming a world-leading oncology company focused on delivering the next wave of therapies for cancer patients, reflecting its innovation and market potential in the biopharmaceutical sector.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma's Board approved the grant of 12,525 stock options to two non-executive employees on April 23, 2026, as equity inducement awards under the 2025 Employment Inducement Incentive Award Plan, highlighting the company's commitment to attracting talent.
- Option Terms: The options have an exercise price of $25.70 per share and a 10-year term, designed to incentivize employees for long-term service and foster innovation in cancer treatment.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service and enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, to rapidly develop potentially transformative treatments for various solid tumors.
See More
